ncRNA-Mediated High Expression of LPCAT1 Correlates with Poor Prognosis and Tumor Immune Infiltration of Liver Hepatocellular Carcinoma

Abstract

Purpose. To investigate the expression of LPCAT1 in liver hepatocellular carcinoma (LIHC) and its relationship with prognosis and immune infiltration and predict its upstream nonencoding RNAs (ncRNAs). Method. In this study, expression analysis and survival analysis for LPCAT1 in pan cancers were first performed by using The Cancer Genome Atlas (TCGA) data, which suggested that LPCAT1 might be a potential LIHC oncogene. Then, ncRNAs contributing to the overexpression of LPCAT1 were explored in starBase by a combination of expression analysis, correlation analysis, and survival analysis. Immune cell infiltration of LPCAT1 in LIHC was finally investigated via Tumor Immune Estimation Resource (TIMER). Result. SNHG3 was observed to be the most promising upstream lncRNA for the hsa-miR-139-5p/LPCAT1 axis in LIHC. In addition, the LPCAT1 level was significantly positively associated with tumor immune cell infiltration, biomarkers of immune cells, and immune checkpoint expression in LIHC. Conclusion. To summarize, the upregulation of LPCAT1 mediated by ncRNAs is associated with poor prognosis, immune infiltration, and immune checkpoint expression in LIHC.

LncRNA AC012360.1 facilitates growth and metastasis by regulating the miR‐139‐5p/LPCAT1 axis in hepatocellular carcinoma

“…[46][47][48] Additionally, miR-139-5p/LPCAT1 predicated worse prognosis in HCC. 29 Herein, we verified that LPCAT1…”

“…On the contrary, another study has claimed that knockout of LPCAT1 restrains HCC progression 26 . Moreover, the miR‐139‐5p/LPCAT1 axis might be regulated by lncRNA SNHG3 in HCC tumorigenesis 29 …”

“…26 Moreover, the miR-139-5p/LPCAT1 axis might be regulated by lncRNA SNHG3 in HCC tumorigenesis. 29 Hence, we speculated that AC012360.1 might participate in the regulation of HCC development via the miR-139-5p/LPCAT1 axis. Herein, AC012360.1 was upregulated in HCC tissues/cells.…”

Clinical significance of down-regulated LPCAT1 expression in acute myeloid leukemia

“…Recently, LPCAT1 has been reported to contribute to cancer initiation and progression in various cancer types. Upregulation of LPCAT1 was found in numerous solid cancers and was correlated with multiple tumor malignant characteristics including progression, metastasis, recurrence and poor prognosis by promoting epithelial-mesenchymal transition, tumor microenvironment, tumor immune infiltration and chemoresistance [11][12][13][14][15][16][17][18][19][20][21][22][23][24]. Mechanistically, LPCAT1 inhibited tumor suppressor gene STAT1 expression, up-regulated Cyclins to promote HCC progression [14].…”

“…Among these members, LPCAT1 has attracted much attention in a variety of cancers. So far, LPCAT1 has been found to be overexpressed in various solid cancers including prostate cancer [11], hepatocellular carcinoma [12][13][14][15][16], breast cancer [17,18], endometrial cancer [19], oral squamous cell carcinoma [20], esophageal squamous cell carcinoma [21], cutaneous squamous cell carcinoma [22], lung adenocarcinoma [23,24] and its overexpression promoted the progression, metastasis, recurrence and worsened survival of these solid cancers. However, the pattern of LPCAT1 expression and its clinical relevance have been rarely studied in AML.…”